Skip to Content
Home  /  Services  /  R&D Portfolio Diagnostic
Fixed-Scope Diagnostic

Where is your R&D budget leaking value — and where is funding slipping away?

See the current state of your R&D — portfolio health, funding and compliance readiness, technology roadmap, and collaboration — in a single picture within two weeks. Not a solution, a clear diagnosis. Delivered fully online.

2 weeksDelivery
4 axesMaturity scorecard
NDAProtected review
OnlineOn-site optional
21 YearsAcademia & OEM Industry
126R&D Projects
€35.5M+Incentives Defended
11 AuditsZero Loss

Drawn from work governed as an operator inside an international agricultural-equipment OEM — where outcomes were owned, not advised. Founders & full bios →

Sectors we have worked in
Machinery Automotive Home Appliances Defense Agriculture

A Clear BoundaryThis is a diagnosis, not a solution

The Diagnostic is an objective assessment process only. It shows you the real risk and opportunity map of your R&D operation — not what you want to hear.

It maps out where your problems and opportunities are; how to resolve them is a separate, later step. You are not obliged to continue with Luminairo to act on the findings; most identified actions can be carried out with your own team. The goal is to clarify the picture independently first.

What this service shows

  • The health and concentration risk of your R&D portfolio
  • Which projects are fundable and which programs match
  • The state of your technology roadmap and capability gaps
  • Whether existing R&D collaborations are working — and which new ones would close capability gaps

What this service does not

  • Grant / funding application writing
  • Detailed action or implementation planning
  • Project-level feasibility or financial analysis
  • Ongoing advisory

Why It's NeededThe visible picture can be clean. The problem is what's invisible.

An R&D organization manages what it can see. The most expensive problems, though, do not show up in the budget — because what is invisible has no trigger. No alarm goes off; the budget line simply reads "in progress." And quietly, it can cost more than all the visible problems combined.

Resource-draining projects

Projects that consume person-months out of inertia, with no strategic return left.

Missed funding

Calls that fit your projects perfectly, opening and closing without ever hitting your radar.

Roadmap blind spots

Capability gaps — AI, autonomy, electrification, digitalization — hidden behind an aging roadmap.

What You ReceiveA single R&D Current-State Assessment Report

A board-ready, scored and prioritized report — and a session where we review it together.

4-Axis Maturity Scorecard (1–5) + Profile

The current state is scored on a 1–5 scale across four axes, with findings and recommended actions for each: R&D Portfolio Health (balance, concentration risk, value vs. resource drain), Funding & Compliance Readiness (fundable projects, matching national/international programs, and the strength and defensibility of R&D documentation ahead of grant audits), Technology Roadmap (current state, target technologies, and capability gaps), and Collaboration & Partnerships (which university, consortium, and external R&D links are active and value-generating, and which are dormant and should be reactivated or closed).

Top 3 Critical Findings

The three highest-priority risks or opportunities, each flagged with its severity (high / medium) and recommended action — not a scattered list, but what to look at first.

Executive Summary & Recommended Next Steps

An executive summary of the findings; recommended next work and — if useful — its estimated scope, timeline, and budget band. Possible collaboration opportunities are noted here too.

How it's delivered: a written report plus a 90-minute online executive review session. Findings are reviewed together; next steps, if any, are discussed.
It is an independent diagnosis: identified actions can be carried out with your own team. Detailed planning and implementation beyond this scope are a separate engagement.
See more representative sample outputs →

Out of ScopeWe set expectations up front

The Diagnostic does not produce:

  • A detailed action or corrective-work plan
  • Grant / funding application files
  • Project-level detailed feasibility or financial analysis
  • Portfolio restructuring execution
  • Collaboration / consortium setup
  • Ongoing advisory

These are the subject of later work, if needed. This engagement does one thing: clarify the picture.

What We Need From YouInputs we review

All data you share is reviewed under a signed Non-Disclosure Agreement (NDA).

  • Technology & product roadmapYour 24–36 month development plans
  • R&D portfolio summariesTechnical summaries of active / planned projects
  • Resource & workforce allocationStaff / project distribution, person-month breakdown
  • Funding history & targetsPast applications and the programs you're targeting

ProcessFrom call to report in four steps

1

Intro call & NDA

We scope it together and sign the NDA.

2

Data handover

You share roadmap, portfolio and funding inputs.

3

Review & analysis

Current state mapped across the four axes.

4

Report + 90-min session

Report delivered and the online review session is held.

Two weeks after complete inputs · fully online

TermsFixed scope, transparent pricing

Fee
€1,400 + VAT, from

Fixed scope. The scope is set; the fee is determined by the three drivers below.

What determines the fee
  • Active project count — up to 20 active projects is standard scope; above that, delivery time and fee may increase.
  • R&D team scale — standard scope covers up to 50 R&D staff; larger organizations may increase delivery time and fee.
  • Delivery mode — fully online by default; on-site visits are arranged at additional cost (travel & accommodation).
NDA-protected 2-week delivery Fixed scope 50% credit
Request an Intro Call

Credit: if you move to a comprehensive Luminairo engagement within 30 days, 50% of this fee is credited toward it.
Payment: 100% in advance upon agreement, to reserve the slot.
Delivery: two weeks after complete inputs; fully online (on-site optional, at additional cost).

Who It's ForIs this service a fit?

A fit

Industrial and AgTech R&D organizations with a structured portfolio, an engineering team, and active R&D / funding activity — ready to face an objective picture of where they stand.

Not a fit

Early-stage, idea-only startups with no portfolio yet; firms that only want a grant application written; managements not ready to see the objective current state.

About the Diagnostic

It is a fixed-scope diagnostic. It maps the current state of your R&D across four dimensions — portfolio health, funding and compliance readiness, technology roadmap, and collaboration — in a single picture within two weeks. It is not a solution, implementation plan, or application file; it is an independent diagnosis that shows where the problems and opportunities are.

The report is delivered two weeks after complete inputs, followed by a closing session. The fee starts at €1,400 + VAT; it is fixed scope, and the price is determined by active project count, R&D team scale, and delivery mode. Standard scope covers up to 20 active projects and 50 R&D staff. The service is delivered fully online; on-site visits are arranged at additional cost.

A single R&D Current-State Assessment Report: a 1–5 maturity scorecard across four axes (R&D Portfolio Health, Funding & Compliance Readiness, Technology Roadmap, Collaboration & Partnerships) with findings and recommended actions per axis, the top three critical findings, and an executive summary with recommended next steps. It is delivered as a written report plus a 90-minute online executive review session.

Fully online by default — document review, analysis, and the executive review session are all conducted remotely. On-site visits can be arranged when needed, at additional cost (travel and accommodation).

No. The goal is to clarify the picture independently first; most identified actions can be carried out with your own team. If you choose to move to a comprehensive Luminairo engagement within 30 days, 50% of the diagnostic fee is credited toward it.

All shared data is reviewed under a signed Non-Disclosure Agreement (NDA). The main inputs reviewed are your technology and product roadmap, R&D portfolio summaries, resource/workforce allocation, and funding history and targets.

Ready to see the real picture of your R&D portfolio?

Request a short introductory call. We'll scope your inputs together and get back to you within 24 hours, with an NDA draft.

Request an Intro Call

This page is for general information only and does not constitute financial or legal advice.